To investigate the association between RBFOX2 expression and the prognosis of tumor patients receiving immunotherapy, we conducted an analysis on the prognostic outcomes and immunotherapy response of patients with non-small cell lung cancer (NSCLC), ccRCC, and melanoma, categorized by their RBFOX2 expression levels. Here, RBFOX2 is linked to non-small cell lung carcinoma.